• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A Review of Meningococcal Disease and Vaccination Recommendations for Travelers.脑膜炎球菌病综述及旅行者疫苗接种建议
Infect Dis Ther. 2018 Jun;7(2):219-234. doi: 10.1007/s40121-018-0196-z. Epub 2018 Mar 17.
2
Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.56 岁及以上成人接种 A、C、W-135 和 Y 群脑膜炎奈瑟球菌四价结合流脑多糖疫苗（MenACWY-TT）的免疫原性和安全性：一项开放性、随机、对照试验的结果。
Drugs Aging. 2013 May;30(5):309-19. doi: 10.1007/s40266-013-0065-0.
3
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.A、C、W-135和Y群脑膜炎球菌结合破伤风类毒素疫苗：一种预防侵袭性脑膜炎球菌病的新型结合疫苗。
Infect Drug Resist. 2014 Apr 3;7:85-99. doi: 10.2147/IDR.S36243. eCollection 2014.
4
Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.用 4CMenB 和 MenACWY 对不同脑膜炎球菌疫苗接种策略对智利当前幼儿 MenACWY 国家免疫规划的公共卫生影响进行建模。
Hum Vaccin Immunother. 2021 Dec 2;17(12):5603-5613. doi: 10.1080/21645515.2021.1996808. Epub 2021 Dec 10.
5
Summary of the National Advisory Committee on Immunization's Update on quadrivalent meningococcal vaccines available in Canada.加拿大国家免疫咨询委员会关于加拿大可用的四价脑膜炎球菌疫苗更新情况的总结。
Can Commun Dis Rep. 2015 Apr 20;41(Suppl 3):17-18. doi: 10.14745/ccdr.v41is3a05.
6
Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix): A Review.脑膜炎球菌四价结合破伤风类毒素疫苗（MenACWY-TT；Nimenrix）：综述。
Drugs. 2017 Nov;77(17):1881-1896. doi: 10.1007/s40265-017-0828-8.
7
Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.两种四价结合脑膜炎球菌疫苗经皮内注射小剂量的安全性和免疫原性。
Vaccine. 2018 Jun 18;36(26):3727-3732. doi: 10.1016/j.vaccine.2018.05.064. Epub 2018 May 16.
8
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.抗击侵袭性脑膜炎球菌病的十年：关于MenACWY-CRM结合疫苗临床及实际应用经验的叙述性综述
Infect Dis Ther. 2022 Apr;11(2):639-655. doi: 10.1007/s40121-021-00519-2.
9
Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents.A 群、C 群、W 群和 Y 群脑膜炎球菌结合型破伤风类毒素疫苗：青少年临床数据的综述。
J Adolesc Health. 2018 Sep;63(3):269-279. doi: 10.1016/j.jadohealth.2018.05.012.
10
A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.一种预防一岁后脑膜炎球菌病的新型疫苗：MenACYW-TT 的早期综述。
Expert Rev Vaccines. 2021 Sep;20(9):1123-1146. doi: 10.1080/14760584.2021.1964962. Epub 2021 Sep 1.

引用本文的文献

1
A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT).一种新型四价脑膜炎球菌破伤风类毒素结合疫苗：Menquadfi®（A群C群W-Y群脑膜炎球菌结合疫苗）
Hum Vaccin Immunother. 2025 Dec;21(1):2516949. doi: 10.1080/21645515.2025.2516949. Epub 2025 Jun 10.
2
Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.用 4CMenB 和 MenACWY 对不同脑膜炎球菌疫苗接种策略对智利当前幼儿 MenACWY 国家免疫规划的公共卫生影响进行建模。
Hum Vaccin Immunother. 2021 Dec 2;17(12):5603-5613. doi: 10.1080/21645515.2021.1996808. Epub 2021 Dec 10.
3
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study.健康幼儿中四价脑膜炎球菌破伤风类毒素结合疫苗（MenACYW-TT）的免疫原性和安全性：一项II期随机研究。
Hum Vaccin Immunother. 2020 Jun 2;16(6):1306-1312. doi: 10.1080/21645515.2020.1733869. Epub 2020 Apr 1.
4
Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Serogroup B.用于预防B群脑膜炎球菌引起的侵袭性脑膜炎球菌病的B群脑膜炎球菌疫苗
Infect Drug Resist. 2019 Oct 9;12:3169-3188. doi: 10.2147/IDR.S159952. eCollection 2019.
5
Child with serogroup W135 primary meningococcal septic arthritis.感染W135群脑膜炎球菌原发性化脓性关节炎的儿童。
BMJ Case Rep. 2019 Oct 15;12(10):e229510. doi: 10.1136/bcr-2019-229510.

本文引用的文献

1
Increase in serogroup W invasive disease in Canada: 2009-2016.2009 - 2016年加拿大W血清群侵袭性疾病增加情况
Can Commun Dis Rep. 2017 Jul 6;43(7-8):144-149. doi: 10.14745/ccdr.v43i78a01.
2
Invasive serogroup W (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 to June 30, 2016.2009年1月1日至2016年6月30日期间，加拿大安大略省的侵袭性W群脑膜炎球菌（MenW）呈现出潜在的克隆替代现象。
Can Commun Dis Rep. 2016 Dec 1;42(12):263-266. doi: 10.14745/ccdr.v42i12a06.
3
Large Outbreak of Neisseria meningitidis Serogroup C - Nigeria, December 2016-June 2017.2016年12月至2017年6月，尼日利亚发生C群脑膜炎奈瑟菌大规模疫情。
MMWR Morb Mortal Wkly Rep. 2017 Dec 15;66(49):1352-1356. doi: 10.15585/mmwr.mm6649a3.
4
Increase in Meningococcal Serogroup W Disease, Victoria, Australia, 2013-2015.2013 - 2015年澳大利亚维多利亚州脑膜炎球菌血清群W疾病的增加情况
Emerg Infect Dis. 2016 Oct;22(10):1785-7. doi: 10.3201/eid2210.151935.
5
The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines.引入脑膜炎球菌疫苗后脑膜炎球菌流行病学的全球演变
J Adolesc Health. 2016 Aug;59(2 Suppl):S3-S11. doi: 10.1016/j.jadohealth.2016.04.012.
6
Clinical characteristics and public health management of invasive meningococcal group W disease in the East Midlands region of England, United Kingdom, 2011 to 2013.2011 年至 2013 年期间，英国英格兰中东部地区侵袭性脑膜炎奈瑟菌 W 群疾病的临床特征和公共卫生管理。
Euro Surveill. 2016 Jun 16;21(24). doi: 10.2807/1560-7917.ES.2016.21.24.30259.
7
Increased incidence of invasive meningococcal disease of serogroup C / clonal complex 11, Tuscany, Italy, 2015 to 2016.2015 至 2016 年，意大利托斯卡纳地区 C 群/11 克隆复合体侵袭性脑膜炎奈瑟菌病发病率上升。
Euro Surveill. 2016;21(12). doi: 10.2807/1560-7917.ES.2016.21.12.30176.
8
Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016.与青少年群组 W 脑膜炎奈瑟菌病（MenW）相关的胃肠道症状和高病死率病例报告，英格兰，2015 年 7 月至 2016 年 1 月。
Euro Surveill. 2016;21(12). doi: 10.2807/1560-7917.ES.2016.21.12.30175.
9
Prevention of meningococcal disease during the Hajj and Umrah mass gatherings: past and current measures and future prospects.朝觐和副朝大规模集会期间脑膜炎球菌病的预防：过去和当前的措施及未来前景
Int J Infect Dis. 2016 Jun;47:71-8. doi: 10.1016/j.ijid.2015.12.010. Epub 2015 Dec 18.
10
The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations.拉丁美洲脑膜炎球菌病的现状及全球脑膜炎球菌病倡议（GMI）的最新建议。
Vaccine. 2015 Nov 27;33(48):6529-36. doi: 10.1016/j.vaccine.2015.10.055. Epub 2015 Oct 25.

脑膜炎球菌病综述及旅行者疫苗接种建议

A Review of Meningococcal Disease and Vaccination Recommendations for Travelers.

作者信息

Serra Lidia C, York Laura J, Gamil Amgad, Balmer Paul, Webber Chris

机构信息

Pfizer Vaccines, Medical Development, Scientific and Clinical Affairs, Collegeville, PA, USA.

Pfizer Vaccines, Global Medical Development, Scientific and Clinical Affairs, Dubai, United Arab Emirates.

出版信息

Infect Dis Ther. 2018 Jun;7(2):219-234. doi: 10.1007/s40121-018-0196-z. Epub 2018 Mar 17.

DOI:10.1007/s40121-018-0196-z
PMID:29550909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5986680/
Abstract

UNLABELLED

International travel has been steadily increasing since the middle of the twentieth century, including travel to regions with high levels of endemic meningococcal disease and areas with sporadic or sustained meningococcal outbreaks. Although invasive meningococcal disease (IMD) is relatively rare in travelers since the advent of quadrivalent meningococcal vaccines, it remains a serious concern because of its rapid progression, poor prognosis and outcomes, associated treatment delays, and the potential to precipitate outbreaks. Moreover, fatality occurs in up to 22% of those infected. This review will focus on IMD in travelers, with an emphasis on IMD epidemiology and the geographic regions of potential concern for international travelers. As vaccination is the best approach for preventing IMD among travelers, currently available meningococcal vaccines and corresponding country-specific national meningococcal vaccination recommendations, where available, will be summarized by age and type of vaccine recommended. The use of the quadrivalent meningococcal vaccines, specifically the tetanus toxoid conjugate vaccine (including MenACWY-TT; Nimenrix), as a protective measure against IMD in travelers will be emphasized.

FUNDING

Pfizer Inc.

摘要

未标注

自20世纪中叶以来，国际旅行一直在稳步增长，包括前往地方性脑膜炎球菌病高发地区以及零星或持续发生脑膜炎球菌疫情的地区。尽管自四价脑膜炎球菌疫苗问世以来，侵袭性脑膜炎球菌病（IMD）在旅行者中相对罕见，但由于其进展迅速、预后和结局不佳、相关治疗延误以及引发疫情的可能性，它仍然是一个严重问题。此外，高达22%的感染者会死亡。本综述将聚焦于旅行者中的IMD，重点关注IMD流行病学以及国际旅行者可能关注的地理区域。由于接种疫苗是预防旅行者中IMD的最佳方法，将按推荐疫苗的年龄和类型总结目前可用的脑膜炎球菌疫苗以及相应国家特定的国家脑膜炎球菌疫苗接种建议（如有的话）。将强调使用四价脑膜炎球菌疫苗，特别是破伤风类毒素结合疫苗（包括MenACWY-TT；Nimenrix）作为旅行者预防IMD的保护措施。

资助

辉瑞公司